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Alemtuzumab Preconditioning With Tacrolimus 
Monotherapy-The Impact of Serial Monitoring for 
Donor-Specific Antibody 
Ron Shapiro, 1,4 Adriana Zeevi, 2 Amit Basu, 1 Henkie P. Tan,l Liise K. Kayler,3 Deanna M. Blisard,l 
Ngoc L. Thai, I Alin L. Girnita/ Parmjeet S. Randhawa/ Edward A. Gray,l Amadeo Marcos, 1 
and Thomas E. Starz[1 
Background. Antibody preconditioning with tacrolimus monotherapy has allowed many renal allograft recipients to 
be maintained on spaced weaning. 
Methods. Of 279 renal allograft recipients transplanted between March 2003 and December 2004, 222 (80%) had 
spaced weaning (Le., reduction of tacrolimus monotherapy dosing to every other day, three times a week, tI-vice a week, 
or once a week) attempted. Routine monitoring for donor-specific antibody (DSA) was begun in September 2004. 
Mean follow-up is 34::t6.5 months after transplantation and 26::tB.l months after the initiation of spaced weaning. 
Results. One hundred and twenty-two (44%) patients remained on spaced weaning. One- and 2-year actual patient/ 
graft survival was 99%/99%, and 97%/96%. Fifty-six (20%) patients experienced acute rejection after initiation of 
spaced weaning. One- and 2-year actual patient/graft survival was 100%/98%, and 94%/7B%. Forty-two (15%) patients 
with stable renal function had spaced weaning stopped because of the development of DSA, which disappeared in 17 
(40%). One- and 2-year actual patient and graft survival was 100% and 100%. 
Conclusion. Adult renal transplant recipients who are able to be maintained on spaced weaning have excellent out-
comes. Patients with stable renal function who have reversal of weaning because of the development of DSA also have 
excellent outcomes. Routine monitoring for DSA may allow patients to avoid late rejection after spaced weaning. 
Keywords: Antibodies, Kidney transplantation, Outcome. 
(Tmnsplantation 2008;85: 1125-1132) 
The potency of alemtuzumab as a preconditioning or an induction agent in renal transplant recipients has been 
demonstrated in a number of reports (I-5). A humanized 
anti-CD52 monoclonal antibody, alemtuzumab (Campath 
IH; Berlex, Montville, NJ) rapidly depletes T and B lympho-
cytes, monocytes, and natural killer cells, and this depletion 
can last for many months. When it has been used in a regimen 
with minimal posttransplant immunosuppression using ta-
crolimus monotherapy, excellent short-term patient and 
graft survival rates and very low rates of early acute rejection 
have been seen in both adult and pediatric patients, with very 
low rates of viral complications and posttransplant diabetes 
mellitus (PTDM) (6-8). Spaced weaning, to every other day 
tacrolimus or less, has also been achieved in a variable per-
centage of patients, ranging from 40% to 60%. Although 
most of the patients undergoing spaced weaning have done 
well, an important and troubling minority have developed 
acute rejection. In an attempt to minimize or prevent the 
development of postweaning rejection, we began to monitor 
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patients for the development of donor-specific antibody 
(DSA) (9). We used the new onset of DSA as a marker for 
impending rejection and abandoned spaced weaning when it 
occurred. In this report, we describe the outcomes of this 
work. 
PATIENTS AND METHODS 
Recipient and Donor Demographics 
Between March, 2003, and December, 2004, 279 adult 
kidney transplantations were performed in 278 recipients 
(Table 1) . The mean recipient age was 50.8::t 15.8 (SD) years 
(range, 18-82). Thirty-eight (14%) were undergoing re-
transplantation, and 39 (14%) were sensitized, with a panel-
reactive antibody (PRA) levels more than 20%. The mean 
donor age was 39.6::!: 15.1 years (range, 1-72). There were 121 
(43%) living and 158 (57%) deceased donors. The mean cold 
ischemia time for the deceased donors was 22.5::!:7.1 hr. The 
average number of human leukocyte antigen (HlA) mismatches 
was3.5::!:1.7. 
We also analyzed outcomes in 152 patients trans-
planted between March, 2000, and July, 2001, before the be-
ginning of the preconditioning era. These patients served as a 
reference group. The mean recipient age was 50.6::t 14.9 years 
(range, 18-86). Thirty-three (22%) were undergoing re-
transplantation, and 40 (26%) had a PRA levels more than 
20%. The mean donor age was 35.5::!: 18.0years (range, 1-78). 
There were 30 (20%) living and 122 (80%) deceased donors. 
The mean cold ischemia time for the deceased donors was 
27.7±8.7 hr. The average number of HLA mismatches was 
3.2±1.6. 
1125 
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TABLE 1. Recipient and donor demographics 
Campath Reference 
Recipient demographics 
Time frame March 2003 to March 2000 to 
Dec 2004 July 2001 
N 279 152 
Age (yrs) 50.S:!: 15.S SO.6±14.9 
Range lS-S2 18-86 
Retransplantation 38 (14%) 33 (22%) 
PRA >20% 39 (14%) 40 (26%) 
Donor demographics 
Age (yrs) 39.6± 15.1 35.5:!:18.0 
Range 1-72 1-78 
Living 121 (43%) 30 (20%) 
Deceased 158 (57%) 122 (80%) 
Cold ischemia time (hrs) 22.5:!:7.1 27.7±8.7 
HLA mismatch 3.5:!:1.7 3.2:= 1.6 
lnununosuppression 
In the preconditioning patients, alemtuzumab 30 mg was 
administered intravenously over 2 hrs intraoperatively, after in-
duction of anesthesia. Premedication was with methylpred-
nisolone 1 g intravenously (IV), diphenhydramine 50 mg IV, 
acetaminophen 650 mg orally, and famotidine 20 mg IV; a sec-
ond dose of methylprednisolone 1 g IV was administered during 
the artelial anastomosis (steroids were administered to mini-
mize cytokine release symptoms). Oral tacrolimus 3 mg twice 
daily was started on postoperative day 1, with a target I2-hr 
trough level of 10 ng/mL (using the Abbott whole blood IMX 
assay) for at least the first 3.5 to 4 months after transplantation. 
At that point, patients were consolidated to once daily tacroli-
mus, that is, a patient on 3 mg twice daily would be converted to 
5 or 6 mg once daily. Two to four months later, patients who 
were stable on once dailytacrolimus would be converted to every 
other day dosing (i.e., from 5 mg once a day to 5 mg every other 
day). By 1 year after transplantation, stable patients could be 
weaned to three times weekly tacrolimus. Less commonly, 
weaning to twice weekly or once weekly tacrolimus was 
carried out; this was generally limited to HLA-identical 
living related donor recipients. 
Beginning in September, 2004, routine monitoring for 
DSA was initiated, beginning 1 and 3 months after transplan-
tation, 1 and 3 months after any major change (i.e., consoli-
dation or spaced weaning), and every 3 months chronically. A 
combination of enzyme-linked immunosorbent assay (ELISA) 
and Lurninex methods was used for the detection and specificity 
analysis of donor-specific anti-HLA antibodies (DSA). We used 
commercial LATM, LATl288, LAT1HD, and LAT240 ELISA 
kits (One Lambda, Canoga Park, CA), in accordance with the 
manufacturer's instructions, to identify IgG anti-HLA class l-
and class II-specific antibodies independently. Briefly, diluents, 
control serum, or patients' san1ples were added to plates coated 
with purified class I or class II HLA antigens. The plates were 
incubated for 60 min, followed by the addition of enzyme-
conjugated anti-IgG secondary antibody. After 40 min, substrate 
was added, the trays were incubated for 10 to 15 min, and the 
reactions were stopped. Anti-HLA IgG antibodies were mea-
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sured indirectly, by a second enzyme-linked colorimetric reac-
tion, and assays were read at 630 nID using an ELISA reader (ELX 
800NB, Bio-Tek Instruments, Inc., Winooski, VT, and One 
Lambda computer software). The positive cutoff was calculated 
as 10% of average positive IgG control (J 0). 
The Luminex system (One Lambda) is a multiplexed 
microsphere-based suspension array platform capable of an-
alyzing and reporting up to 100 different reactions in a 
single reaction vessel (11). The serum is first incubated 
with LABScreen beads. Any anti-HLA antibodies present 
in the serum bind to the antigens and then are labeled with 
R-phycoerythrin-conjugated goat anti-human IgG. The 
Labscan 100 flow analyzer detects the fluorescent emission 
of R-phycoerythrin from each bead, allowing real-time 
data acquisition. We used LSMl2 beads for the detection 
of class I and class II anti-HLA antibody, LSIPRA and 
LS2PRA for specificity analysis, and LSIA/Ls2A for single-
antigen analysis. We applied the manufacturer's positive 
cutoff for LABScreen, the normalized background ratio, 
which is considered positive when greater than 15%. 
Patients with class I and class II ELISA screens less than 
10% were generally assumed not to have DSA; in patients 
with ELISA less than 10%, further analysis was performed to 
look for DSA. Although it is possible that patients with ELISA 
screens less than 10% might have had low leYel DSA by more 
sensitive testing (Le., Luminex), this testing was initially not 
available to our laboratory at the time, and began to be used 
only in the last 16 months. In patients on spaced weaning who 
developed a de novo DSA, weaning was abandoned, and pa-
tients were taken back to once dailytacrolimus. If the DSA did 
not disappear over the next few months, mycophenolate 
mofetil250 to 500 mg twice daily was added to the immuno-
suppressive regimen. In patients on once daily tacrolimus, the 
development of DSA would preclude any attempt at spaced 
weaning, and would generally lead to an increase in immu-
nosuppression to twice daily tacrolimus, with or without the 
addition of mycophenolate mofetil. 
Rejection was biopsy proven more than 95% of the 
time. Acute rejection was treated initially with steroids and an 
adjustment of the tacrolimus dosage. Steroid resistant rejec-
tion was treated with antibody therapy, either additional ale-
mtuzumab, thymoglobulin, or OKT3, and the addition of 
mycophenolate mofetil or sirolimus. Antibody-mediated re-
jection was treated with plasmapheresis/IVIg, and an adjust-
ment in the tacrolimus dosage, 'with or without the addition 
of mycophenolate mofetil or sirolimus. In patients on spaced 
weaning with acute rejection, the tacrolimus dosage was con-
verted back to once daily, in addition to the other therapies 
just described. 
In the reference group, immunosuppression was gen-
erally with tacrolimus, mycophenolate mofetil, and steroids, 
without antibody induction. Occasional patients received 
sirolimus instead of mycophenolate mofetil as part of a pilot 
triaL The diagnosis and treatment of acute rejection was car-
ried out as described above. 
Statistics 
This study was conducted as a retrospective medical 
records review, and data were managed under the auspices of 
our institutional review board-authorized honest brokering 
system. Categorical data were expressed as frequency and per-
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centages. Nonparametric variables were expressed as mean 
value and standard deviation. 
Institutional Oversight 
This immunosuppressive regimen, which was used as 
the standard of care for our patients, was approved by the 
Innovative Clinical Practice Committee and the Pharmacy 
and Therapeutics Committee of the University of Pittsburgh 
Medical Center (12). Data analysis was performed under an 
institutional review board-approved protocol. Institutional 
support was always present throughout this time period. 
RESULTS 
The mean follow-up was 34::!::6 months in the alemtu-
zumab preconditioning patients, and 67::!::5 months in the 
reference group. 
Patient and Graft Survival 
Overall 1- and 2-year patient and graft survival rates in 
the preconditioning group were 97% and 94%, and 94% and 
87%, respectively (Fig. 1a). Corresponding survival rates in 
the reference group were 95% and 91 %, and 89% and 81 %, 
respectively. In general, outcomes in the preconditioning pa-
tients were at least as good, and perhaps slightly better than in 
the reference group. Subgroup analyses of graft survival in the 
preconditioning group were performed in living versus de-
ceased donor cases, primary versus retransplantation, African 
Americans versus non-African Americans, recipients with 
Results - Overall Survival 
··Campath 
-- Reference 
Patient Survival Graft Survival 
100%· 
90% 
D~ .. ~ 100%,' 
~9M% 
80% 
70% 70% 
a o 6 12 18 24 30 36 42 48 o 6 12 18 24 3Q 36 42 48 
Results - Graft Function 
~ Campath ....- Reference 
S~---------------------------------K 
o +----K-----r----K----I----I-----r-~ 
b Years 
FIGURE 1. (a) Patient and graft survival in the alemtu-
zumab and reference groups. (b) Serum creatinine over 
time in the alemtuzumab and reference groups. 
Shapiro et al. 
TABLE 2. Campath subgroup survival 
l-yr graft 
% survival % 
Donor type 
Living 43 98 
Deceased 57 90 
Graft type 
Primary 86 95 
Nonprimary 14 87 
Recipient race 
African American 13 83 
Non-African American 87 95 
Preoperative PRA 
2::20% 14 89 
<20% 86 94 
HLA mismatches 
0 10 96 
3 100 
2 13 94 
3 18 100 
4 22 90 
5 24 94 
6 10 93 
Acute rejection-reference 
Overall 28 
Steroid-resistant 3 
Preweaning rejection-
Campath 
Overall 8 
Steroid-resistant " <-
Delayed graft function 
Campath 12 
Reference 31 
Campath 
Complications (%) 
CMV disease 0 
BKvirus 0.7 
PTLD 0.4 
PTDM 1.2 
1127 
2-yr graft 
survival % 
90 
86 
89 
82 
81 
89 
82 
88 
96 
88 
86 
90 
80 
92 
82 
Reference 
(%) 
5.3 
2.6 
2.6 
11.8 
PRA, panel-reactive antibody; HLA, human leukoc),te antigen; CMV, 
cytomegalovirus; PTLD, posttransplant Iymphoproliferative disorders; 
PTDM, posttransplant diabetes mellitus . 
PRA levels more than or equal to 20% or less than 20%, and 0 
to 6 antigen mismatch cases, and are shown in Table 2. 
Renal Function 
Renal function over time was similar between the pre-
conditioning and the reference groups (Fig. Ib). The mean 
serum creatinine 2 years after transplantation was 1.5 mg/dL 
in both groups of patients. 
Acute Rejection 
The incidences of acute rejection and of steroid resis-
tant rejection before spaced weaning in the preconditioning 
1128 
group were 8% and 2%, respectively, and in the reference 
group were 28% and 3% (Table 2). 
Infectious Complications, Posttransplant 
Diabetes Mellitus, and Delayed Graft 
Function 
The incidences of cytomegalovirus, BK virus, post-
transplant lymphoproliferative disorders, and PTDM in the 
preconditioning and reference groups, as shown in Table 2, 
were generally lower in the preconditioning group. Delayed 
graft function (DGF) was also observed less commonly in the 
preconditioning group. 
Spaced Weaning 
Spaced weaning was not attempted in 57 (20%) patients. 
These were generally patients with poor graft function or who 
had experienced difficult early rejection episodes. Spaced wean-
ing was attempted in 222 (80%) patients an average of 8.0::t: 3.0 
months after transplantation. Spaced weaning was able to be 
continued in 122 (44% of the overall population of279 patients, 
55% of the 222 patients in whom spaced weaning was at-
tempted) patients. Weaning was interrupted in 56 (20%125%) 
patients because of acute rejection, and in 42 (15%/190/0) pa-
TABLE 3. Monitoring for donor-specific antibody (DSA) 
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tients because of the development of DSA. One additional pa-
tient had interruption of spaced weaning because of an elevated 
Cylex level of 508, and another had interruption of spaced wean-
ing because he was thought to have developed DSA, although he 
had not done so. One- and 2-year patient and graft survival rates 
in the four groups are shown in Table 3. The worst outcomes 
were in patients who were never weaned. The patients who were 
weaned and who remained on spaced weaning had excellent 
outcomes, as did those who had weaning interrupted because of 
the development of DSA. In patients who had weaning inter-
rupted because of acute rejection, patient survival was reason-
able (94% at 2 years), but graft survival was down to 78% at 2 
years. A subgroup analysis of spaced weaning is shown in Table 
3. Eighty percent of patients receiving 0 antigen mismatch kid-
neys were able to undergo spaced weaning. Individual cases of 
successful spaced weaning, weaning interrupted by acute rejec-
tion, and weaning interrupted by the development of DSA are 
shown Figure 2 (a-c). 
Donor-Specific Anti-Human Leukocyte Antigen 
Alloantibodies 
Donor-specific anti-HLA alloantibodies (DSA) were 
detected in 42 (15%) patients by ELISA or Luminex (Table 4). 
N (%) Patient/graft 1 yr Survival % 2 yr HLA mismatch 
Never vieaned 
Remained on spaced dosing 
Ended spaced dosing at rejection 
Ended spaced dosing at DSA 
Campath subgroup weaning 
Donor type 
Living 
Deceased 
Graft type 
Primary 
Nonprimary 
Patitn tract 
African American 
Non-African American 
Preoperative PRA 
~OM% 
<20% 
HLA mismatches 
o 
3 
4 
5 
6 
6 
57 (20) 
122 (44) 
56 (20) 
42(15) 
Spaced dosing % 
62 
48 
55 
52 
48 
55 
40 
57 
80 
29 
65 
48 
50 
52 
45 
PRA, panel-reactive antibody; HLA, human leukocyte antigen. 
86/70 
99/99 
100/98 
100/100 
79/63 
97/96 
94/78 
100JIOO 
3.6:!: 1.4 
3.2:!: l.9 
3.6:!: 1.4 
4.1:!:1.5 
Ended spaced dosing % 
At rejection 
24 
27 
25 
28 
24 
25 
29 
25 
7 
12 
23 
31 
23 
17 
17 
AtDSA 
15 
23 
19 
17 
12 
20 
36 
16 
4 
12 
12 
12 
16 
20 
28 
L 
t . 
f 
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FIGURE 2. (a) Uncomplicated patient course. (b) Spaced weaning interrupted by rejection. (c) Spaced weaning inter-
rupted by the development of DSA. 
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TABLE 4. Distribution of donor-specific anti-HLA 
alloantibody (DSA) after weaning cessation 
Anti-HLA DSA 
Case class I DSA Anti-HLA class II DSA disappeared 
2 
3 Al 
4 B35 
5 
6 Al 
7 
8 B8 
9 B27 
10 
11 B61 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
B7 
B53 
B65 
B8 
B44 
A26,B7 
B7, Cw2 
A26 
DQ4 
DRl7, DQ2 
DR4, DRl7, DR52 
DR7,DR53 
DRl7 
DRI5 
DRl3 
DR17 
DQ4 
DQ2 
DR4, DQ7 
DRI7, DQ2 
DRl7, DQA1'5 
DRll, DR52, DQAl *3, 
DQAl*5 
DR13, DQ5, DQ7, 
DQAl*5 
DRll, DQ7 
2S 
26 
27 
28 
A2, A26, B49 DRIS, DRSl 
DR4,DRS3 
29 
30 
A68, B44, CwS DR4, DQ6, DQAI *3 
DR7,DRS3 
31 
32 
33 
34 
35 
36 
37 
38 
A'6801 
39 Cw3 
40* B49 
41* 
42* A24, B7 
DQ7 
DQ3 
DR7, DRS3 
DRS3, DQ2, DQ7, DQAl *5 
DRS, DQ7 
DQ6 
DRS2, DQ7, DQAl *S 
DRlS, DRl7, DQAl *0501 
DQ6 
DR17, DQ2 
HLA, human leukocyte antigen. 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
Patients with an ELISA screen PRA lower than 10% were 
assumed not to have DSA; in the past 16 months, this was 
selectively confirmed by Luminex: testing. In these patients we 
did not detect DSA before transplantation, and the T - and 
B-cell crossmatches were negative. After transplantation and 
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TABLE S. Comparative ELISA PRAs in patients in whom 
DSA did or did not disappear 
DSA 
Class I DSA 
Class II DSA 
HLA-ADSA 
HLA-BDSA 
HLA-DRBI DSA 
HLA-DRB3,4,S DSA 
HLA-DQBl DSA 
DSA disappeared 
No 
38 
33 
29 
31 
32 
35 
30 
30 
Yes 
33 
36 
17 
14 
40 
33 
20 
14 
p 
NS 
NS 
0.08 
0.10 
NS 
NS 
0.12 
0.11 
ELISA, enzyme-linked immunosorbent assay; PRA, panel-reactive anti· 
body; DSA, donor-specific antibody; HLA, human leukocyte antigen. 
initiation of spaced weaning, 12 patients developed an ti-clas~ 
I DSA, 22 patients developed anti -class II DSA, and 8 patient~ 
developed both anti-class I and anti-class II DSA. After wean· 
ing was abandoned in response to the development of DSA 
circulating DSA disappeared in 17 (40%) patients, and per· 
sisted in the other 25 (Table 4). The DSA specificity distribu· 
tion was as follows: 9 anti-HLAA, 14 anti-HLA B, 3 anti-HLP 
C, 24 anti-HLA DRBl, 8 anti-HLA DQAl, 20 anti-HLP 
DQBl, and 10 anti-HLA DRB3,4,5. Interestingly, some DS} 
specificities disappeared more than others. The descendin) 
order of DSA disappearance was: 
• Anti-HLA-B DSA disappeared in 9 of 14 cases (64%); 
• Anti-HLA-DRBI DSA disappeared in 10 of 24 case 
( 42%); 
• Anti-HLA-A DSA disappeared in 3 of9 cases (33%); 
• Anti-HLA-DRB3,4,5 DSA and anti-HLA-DQB1 D5i 
disappeared in 22% (2 of9) and 21% (4 of 19) of case: 
respectively; 
• Anti-HLA-DQA1 DSA and anti-HLA-C DSA did no 
disappear in any case (0 of8 and 0 00, respectively). 
The anti-HLA antibody strength was expressed as a ra 
tio of the patients' ELISA to the positive control. There was 
trend toward a lower ELISA PRA in patients whose DSA di, 
appeared for anti-HLA A, DRB3,4,5, and DQB 1 (Table 5). 
DISCUSSION 
The paradigm shift of preconditioning with minim; 
posttransplant immunosuppression was undertaken becaUi 
of a concern that modern multi agent immunosuppressiv 
regimens preclude any donor-recipient immune system ir 
teraction, and thus compromise long-term graft survival (I 
7, 13, 14). Registry data have confirmed these observation 
and have suggested that, despite falling acute rejection rate 
renal allograft halflife has not improved over the past decac 
(15). Short-term outcomes in an unselected patient populi 
tion with a regimen of alemtuzumab preconditioning an 
tacrolimus monotherapy after kidney transplantation hal 
been quite reasonable, with 1- and 2-year patient and gra 
survival rates of 97% and 94%, and 94% and 87%, respe, 
tively, and have compared favorably with outcomes seen in 
conventionally immunosuppressed reference group. Rates 
© 2008 Lippincott Williams & Wilkins 
early acute rejection, viral complications, and DGF have all 
been low, and again have compared favorably with those seen 
in the reference group. Spaced weaning has been attempted in 
most of the preconditioning patients, and those patients who 
were able to be maintained on spaced weaning had excellent 
outcomes. Patients who had weaning abandoned because of 
acute rejection had reasonable patient survival but compro-
mised graft survival at 2 years. Screening for the development 
of DSA, and interruption of weaning when DSA was noted 
was associated with good outcomes. We found that the per-
sistence of donor-specific HLA antibody depends on the 
specificity itself. The fastest to disappear were anti-class I 
HLA-A and HLA-B antibodies, as well as anti-class II DRBI 
antibodies. However, anti-HLA DQ alpha and beta, anti-
DRB3,4,S, and anti-HLA C antibody specificities were signif-
icantly more persistent. A similar pattern was described in the 
Johns Hopkins desensitization protocol, after plasma ex-
change/IVIg (16). In three cases (40,41, and 42, Table 4), 
some of the DSA disappeared, whereas other DSA, mostly 
anti-HLA DQ, persisted. Antibody strength might also be im-
portant, as was reported by Terasaki's group (17). In the 
present study, we also noted a tendency for lower antibody 
strength in some patients whose DSA disappeared. It is also 
noteworthy that all living-related grafts were in the subgroup 
where DSA disappeared (cases 7, 10, 16, Table 4). Further-
more, a single allelic difference was sufficient for humoral 
allosensitization (Table 4, case 34); the recipient typing was 
HLA-A *6802, and the donor typing was HLA-A*680l; all 
the other HLA-A, -B, -Cw, -DRBl, -DQAl, -DQBl, and 
-DRB3,4,Sloci were matched at the allelic leveL 
In 40% of patients, DSA disappeared after patients 
were put back on daily tacrolimus. This observation, that 
DSA can disappear when immunosuppression is intensi-
fied, is relatively novel and important. Others have shown 
that conversion from cyclosporine/azathioprine to tacroli-
mus/mycophenolate mofetil-based immunosuppression 
can reduce DSA (18). In our patients, increasing the dosage 
of tacrolimus from every other day or three times a week to 
daily dosing was often sufficient to reduce DSA. This observation 
offers the possibility of allowing maintained stable renal function 
and graft survival in patients who do not tolerate spaced wean-
ing, and can continue to allow most patients to benefit from an 
immunosuppressive regimen that allows for minimal posttrans-
plant immunosuppression. 
Unfortunately, it is possible to develop postweaning 
rejection in the absence of DSA. Additional immunologic 
monitoring tools will have to be developed to allow safer im-
munosuppression minimization. We are currently studying 
the Cylex assay (19) as a routine clinical test, and are explor-
ing other potentially useful immunologic markers. 
There are a number of important limitations of this 
analysis. First, in most of the patients who developed post-
weaning rejection, the incidence of DSA was not known, be-
cause routine analysis for DSA was begun late in the series. 
Second, this was not a randomized trial, and so these obser-
vations lack a control group. The alemtuzumab and reference 
group recipient and donor demographics had some similari-
ties, but were not identical. The reference groups cannot be 
compared with the Campath group statistically, because these 
were two different groups transplanted at two different time 
points, and assignment was not randomized. Third, routine 
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staining for C4d was not performed by our pathologists dur-
ing this time period. 
To conclude, an immunosuppressive regimen with ale-
mtuzumab preconditioning and tacrolimus monotherapy in 
unselected adult renal transplant recipients seems to be asso-
ciated with excellent short-term patient and graft survival, 
low rates of early acute rejection, viral complications, PTDM, 
and DGF, and excellent renal function. Spaced weaning is 
possible in the most of the patients, with generally good out-
comes. Monitoring for DSA may serve as a marker for im-
pending rejection after weaning, and interruption of weaning 
in patients with stable renal function who develop DSA can 
lead to its disappearance, with maintained stable renal func-
tion and excellent graft survival. 
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